An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor CAR T-Cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma FIRCE-1

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05972720

Study #:
STUDY00150573

Start Date:
Nov 13, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05972720

View Complete Trial Details & Eligibility at ClinicalTrials.gov